First Danish Hospital Signs INTERCEPT Platelet Agreement With Cerus

  First Danish Hospital Signs INTERCEPT Platelet Agreement With Cerus

Business Wire

CONCORD, Calif. -- May 28, 2013

Cerus Corporation (NASDAQ:CERS) announced today that Aalborg University
Hospital, Denmark, signed a five year project collaboration agreement for the
INTERCEPT Blood System for platelets.

The first hospital in Denmark to adopt INTERCEPT, the department of FBE
Klinisk Immunologi at Aalborg University Hospital transfuses an estimated
2,200 platelet units annually to Region Nordjylland, representing
approximately 6% of Denmark’s platelet market.

“Bacterial contamination of platelets is one of the most prevalent infectious
risks in blood transfusion, posing serious health risks to transfusion
patients. We believe the INTERCEPT Blood system will significantly decrease
residual risk due to bacterial contamination, and offer key operational
advantages such as reduced waste rates,” stated Dr. Kim Varming of the
department of FBE Klinisk Immunologi.

“We are extremely pleased with Aalborg University Hospital's position on blood
safety, as shown by its proactive approach to protecting their patients
against transfusion transmitted infections,” said Caspar Hogeboom, president
of Cerus Europe. “Through 10 years of routine use, INTERCEPT demonstrated
improved patient outcomes as supported by hemovigilance data in which
INTERCEPT-treated platelet components prevented septic transfusion reactions.
Logistics and component availability are also positively impacted resulting in
cost-effective blood center operations. We look forward to working with
Aalborg University Hospital in their mission for improved blood safety, and
hope to extend implementation of INTERCEPT platelets to other Danish centers
in the future.”

ABOUT CERUS

Cerus Corporationis a biomedical products company focused on enhancing blood
safety. TheINTERCEPT system is designed to reduce therisk of
transfusion-transmitteddiseases by inactivating a broad range of pathogens
such as viruses, bacteriaand parasites that may bepresent in donated blood.
The nucleic acid targetingmechanism of action enables INTERCEPT treatment to
inactivate establishedtransfusionthreats, such as hepatitis B and C, HIV,
West Nile virus andbacteria, and is designed to inactivate emerging pathogens
such as influenza,malaria and dengue. Cerus currently markets and sells the
INTERCEPT BloodSystem for both platelets and plasma in Europe,
theCommonwealth of IndependentStates, the Middle East and selected countries
in other regions around theworld. In the United States, Cerus is seeking
regulatory approval of the INTERCEPT Blood System for plasma and platelets.
The INTERCEPT red blood cell system is in clinical development.
Seehttp://www.cerus.comfor more information.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Except for the historical statements contained herein, this press release
contains forward-looking statements concerning Cerus’ products, prospects and
results, including statements regarding the expected implementation schedule
of the INTERCEPT platelet system at FBE Klinisk Immunologi Blodbanken. Actual
results could differ materially from these forward-looking statements as a
result of certain factors, including, without limitation, risks associated
with demand for the INTERCEPT Blood System, including the risk that purchases
of the platelet system may be less than anticipated thereunder, risks relating
to Cerus’ ability to meet its supply obligations, as well as other risks
detailed in Cerus’ filings with the Securities and Exchange Commission,
including Cerus’ Quarterly Report on Form 10-K for the quarter ended March 31,
2013 filed with the SEC on May 3, 2013. Cerus disclaims any obligation or
undertaking to update or revise any forward-looking statements contained in
this press release.

Contact:

Cerus Corporation
Lainie Corten, 925-288-6319
Sr Director, Global Marketing & Investor Relations
 
Press spacebar to pause and continue. Press esc to stop.